<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787250</url>
  </required_header>
  <id_info>
    <org_study_id>APT.PJI.001</org_study_id>
    <nct_id>NCT04787250</nct_id>
  </id_info>
  <brief_title>Bacteriophage Therapy in Patients With Prosthetic Joint Infections</brief_title>
  <official_title>Randomized Open Label, Parallel Group, Controlled Study to Evaluate the Safety and Surgery Sparing Effect of Phage Therapy With Antibiotics for Patients With Prosthetic Joint Infections Who Are Candidates for Two Stage Exchange Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptive Phage Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Adaptive Phage Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study designed to evaluate bacteriophage therapy in patients with chronic&#xD;
      prosthetic joint infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study designed to evaluate bacteriophage therapy in patients with chronic&#xD;
      prosthetic joint infections of the hip or knee caused by 1 or 2 of the following organisms:&#xD;
      Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus&#xD;
      sp., Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa,&#xD;
      and/or Klebsiella pneumoniae.&#xD;
&#xD;
      This study will also compare the safety and efficacy of phage therapy in conjunction with&#xD;
      antibiotics versus standard of care (SOC) two-stage exchange arthroplasty plus antibiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2022</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, open-label, parallel-group design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of phage therapy</measure>
    <time_frame>Day 1 through Week 26</time_frame>
    <description>Incidence and type of adverse events and infusion reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of phage therapy to prevent need for surgery in patients with hip/knee prosthetic joint infections.</measure>
    <time_frame>6 weeks after completion of phage therapy</time_frame>
    <description>Proportion of phage-treated patients with no need for surgery by no evidence of a prosthetic joint infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of phage therapy in hip joint functionality as assessed by hip disability and osteoarthritis outcome questionnaire score (HOOS).</measure>
    <time_frame>Week 26</time_frame>
    <description>Time to reach minimum clinically important difference in hip dysfunction and osteoarthritis outcome score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of phage therapy in knee joint functionality as assessed by knee injury and osteoarthritis outcome questionnaire score (KOOS).</measure>
    <time_frame>Week 26</time_frame>
    <description>Time to reach minimum clinically important difference in knee injury and osteoarthritis outcome score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1, Phage Therapy with Antibiotic Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phage therapy will be administered in conjunction with antibiotic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2, Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two-stage exchange arthroplasty entails resection arthroplasty and placement of an antibiotic-loaded spacer, antibiotic therapy, an antibiotic-free observation period, and re-implantation of a new prosthesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Phage Therapy</intervention_name>
    <description>Phage will be administered based on patient's matching results.</description>
    <arm_group_label>Arm 1, Phage Therapy with Antibiotic Treatment</arm_group_label>
    <other_name>Antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Two-Stage Exchange Arthroplasty</intervention_name>
    <description>Performed per the study center's standard of care. No investigational products are used.</description>
    <arm_group_label>Arm 2, Standard of Care</arm_group_label>
    <other_name>Antibiotics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          -  Males or females â‰¥18 years of age.&#xD;
&#xD;
          -  Female patients of childbearing potential who agree to use contraception.&#xD;
&#xD;
          -  Candidate for a two-stage exchange arthroplasty.&#xD;
&#xD;
          -  Chronic prosthetic joint infection&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of prosthetic joint infections (PJI) of same joint treated surgically&#xD;
             other than one prior Debridement Antibiotics and Implant Retention procedure&#xD;
&#xD;
          -  Soft tissue defect requiring reconstruction&#xD;
&#xD;
          -  Hardware misalignment or loosening&#xD;
&#xD;
          -  Active osteomyelitis&#xD;
&#xD;
          -  Septic shock or hemodynamic instability&#xD;
&#xD;
          -  Stage 4 or greater chronic kidney disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  Alcohol abuse or alcohol induced liver disease or non-alcoholic steatohepatitis&#xD;
&#xD;
          -  Decompensated heart failure&#xD;
&#xD;
          -  Any other clinically significant disease, per judgement of the investigator&#xD;
&#xD;
          -  Neutropenia (neutrophil count &lt; 1000 cells/cubic mm), thrombocytopenia (platelets &lt;&#xD;
             50,000/cubic mm) or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) &gt;&#xD;
             3 time the upper limit of normal&#xD;
&#xD;
          -  HIV, hepatitis C, hepatitis B infection&#xD;
&#xD;
          -  Positive drug screen&#xD;
&#xD;
          -  Receipt of chemotherapy, immunosuppressants or immune modulators&#xD;
&#xD;
          -  Anti-viral medication&#xD;
&#xD;
          -  Any known phage allergy&#xD;
&#xD;
          -  Breast feeding or pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Hopkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Adaptive Phage Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Holland</last_name>
    <phone>202-391-8058</phone>
    <email>sholland@aphage.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gina Suh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prosthetic</keyword>
  <keyword>Joint</keyword>
  <keyword>Knee</keyword>
  <keyword>Hip</keyword>
  <keyword>Phage</keyword>
  <keyword>Bacteriophage</keyword>
  <keyword>Prosthetic Joint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

